Eledon Pharmaceuticals, Inc. ELDN 深 滬
已收盤 02-06 16:00:00 美东时间
2.19
+0.220
+11.17%
華盛通- 最 高2.195
- 今 開1.98
- 成交量 73.81万股
- 最 低 1.98
- 昨 收 1.97
- 總市值 1.74亿
- 52周最高 4.65
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 1.35
- 委 比 -40.81%
- 總股本 7963.03万
- 歷史最高 154.98
- 量 比 1.46
- 振 幅 10.91%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eledon Pharma To Present 24-Month Follow-Up Data From Eight Patients Enrolled In Phase 1b Trial Long-Term Extension Evaluating Tegoprubart In Kidney Transplantation At 2026 ASTS Winter Symposium
Data from eight participants continue to support safety and tolerability profile of tegoprubartMean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24
01-23 20:06
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Eledon Pharmaceuticals announced 24-month follow-up data from eight kidney transplant patients in an ongoing Phase 1b trial extension, demonstrating the safety and tolerability of tegoprubart, an anti-CD40L antibody. The data showed an increase in mean eGFR from 67.0 to 74.2 mL/min/1.73 m² over the study period with no episodes of biopsy-proven acute rejection or graft loss. Eledon will present the findings at the American Society of Transplant S...
01-23 12:00
Eledon Pharmaceuticals Expects To Present 24-Month Data From 8 Participants In Phase 1 Extension Study Evaluating Tegoprubart In Kidney Transplantation In 2026; Report Other Data From Phase 1, 2 BESTOW Trials
Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.
01-09 05:13
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Eledon Pharmaceuticals announced key 2025 achievements, including favorable Phase 2 BESTOW trial results for tegoprubart in kidney transplantation, demonstrating reduced toxicities compared to tacrolimus. The company also reported positive outcomes in type 1 diabetes patients treated with tegoprubart following islet transplantation, with all six initial patients achieving insulin independence. Additionally, tegoprubart was used successfully in xe...
01-08 21:05
Eledon Pharmaceuticals Restructures Stake via Pre-Funded Warrant
Eledon Pharmaceuticals ( ($ELDN) ) has provided an update. On December 30, 2025...
01-03 06:03
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have...
2025-12-31 21:07
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Eledon Pharmaceuticals announced that CEO David-Alexandre C. Gros, M.D., will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on December 4, 2025. The webcast can be registered in advance via the provided link, with a replay available post-event on the company’s website. Eledon is a clinical-stage biotech company developing immune-modulating therapies, with its lead product, tegoprubart, targeting CD40L for c...
2025-12-01 12:00
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Guggenheim Maintains Buy on Eledon Pharmaceuticals, Lowers Price Target to $8
Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.
2025-11-18 22:10
Eledon Pharmaceuticals GAAP EPS of -$0.21
Eledon Pharmaceuticals press release (ELDN): Q3 GAAP EPS of -$0.21. Cash, cash equivalents and short-term investments totaled $93.4 million as of September 30, 2025 compared to $140.2 million as of De...
2025-11-15 06:43
